相关实验视频
Updated: Oct 13, 2025

09:36
Isolated Pancreatic Islet Treatment and Apoptosis Measurement
Published on: May 2, 2025
509
作为抗糖尿病剂的生物活性的出现:一篇评论
Ramanand -1, Rohit Singh1,2, Vedpal Singh3
1Medicinal and Process Chemistry, CSIR-Central Drug Research Institute, Lucknow (U.P)-226031, India.
Current protein & peptide science
|September 5, 2025
概括
来自自然来源的生物活性在控制血糖水平方面具有前景. 本综述探讨了它们的抗糖尿病特性和潜在的新药开发机制.
科学领域:
- 生物化学
- 药理学
- 营养科学
背景情况:
- 糖尿病是全球日益严重的健康问题,对经济和社会产生重大影响.
- 饮食干预和体力活动对于糖尿病管理至关重要.
- 来自自然来源的生物活性具有治疗效益,包括抗糖尿病潜力.
研究的目的:
- 审查生物活性的起源,结构特征和作用机制.
- 更新对控制血糖水平的生物活性的理解.
- 评估生物活性对血糖调节的潜力.
主要方法:
- 对生物活性和糖尿病的科学研究进行文献审查.
- 对参与葡萄糖代谢的关键酶和蛋白质的效应分析.
- 对抗糖尿病活动的分子机制的检查.
主要成果:
- 生物活性可以降低血糖,改善胰岛素敏感性,并抑制与糖尿病相关的酶.
- 特定的会影响诸如α- 葡萄糖酶,α- 氨基酶和二基酶-IV之类的酶.
- 了解的机制是开发新型抗糖尿病药物的关键.
结论:
- 生物活性是一种有前途的糖尿病治疗方法.
- 进一步研究分子机制将有助于开发基于的药物.
- 这些发现支持对有效血糖控制的生物活性的评估.
相关概念视频
Glucagon-like Receptor Agonists
475
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
475
Dipeptidyl Peptidase 4 Inhibitors
289
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
289
Insulin: Biosynthesis, Chemistry, and Preparation
658
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
658
Oral Hypoglycemic Agents: Glinides
301
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
301
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.5K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.5K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
314
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
314

